Merck expects COVID pill to reach rich and poor countries simultaneously

Paul Schaper, the company’s executive director of global public policy, told AFP that Merck began working on its access strategy from July 2020, long before the efficacy results of the drug it developed with Ridgeback Biotherapeutics were announced in October 2021.

Read the full story: Read More